PABPC1P2: A Potential Drug Target and Biomarker for Poly(A) Binding Protein-Cytoplasmic 1 Pseudogene 2

Target Name: PABPC1P2

NCBI ID: G728773

PABPC1P2

PABPC1P2: A Potential Drug Target and Biomarker for Poly(A) Binding Protein-Cytoplasmic 1 Pseudogene 2

Poly(A) binding proteins (PABPs) play a crucial role in various cellular processes, including DNA replication, transcription, and translation. PABPs are involved in ensuring the stability and accuracy of gene expression by interacting with specific DNA sequences, including the cytoplasmic 1 pseudogene 2 (PABPC1P2) gene. The cytoplasmic 1 pseudogene 2 is a non-coding RNA molecule that is predominantly expressed in the cytoplasm of human cells. However, its functions in cellular processes are not well understood.

Recent studies have identified PABPC1P2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. In this article, we will provide an overview of PABPC1P2, its functions, and its potential as a drug target.

F functions and localization

PABPC1P2 is a 21-kDa protein that is expressed in various tissues and cells, including brain, heart, and cancer cells. It is composed of 121 amino acid residues and has a calculated pI of 9.97. PABPC1P2 is primarily localized to the cytoplasm of human cells, where it interacts with various DNA sequences, including the cytoplasmic 1 pseudogene 2.

PABPC1P2 functions as a negative regulator of gene expression

PABPC1P2 has been shown to function as a negative regulator of gene expression by binding to specific DNA sequences. PABPC1P2 has been identified to interact with the cytoplasmic 1 pseudogene 2, a region that contains several highly conserved non-coding RNA binding sites. These interactions result in the repression of gene expression, thereby ensuring the stability and accuracy of cellular processes.

PABPC1P2 is a potential drug target

PABPC1P2 has been identified as a potential drug target due to its involvement in various diseases. PABPC1P2 has been shown to be involved in cancer, neurodegenerative diseases, and psychiatric disorders.

PABPC1P2 is a potential drug target for cancer

PABPC1P2 has been shown to be involved in the regulation of cancer cell growth and survival. Several studies have shown that PABPC1P2 is involved in the regulation of various cellular processes, including cell division, apoptosis, and angiogenesis. Therefore, PABPC1P2 has potential as a drug target for cancer.

PABPC1P2 is a potential drug target for neurodegenerative diseases

PABPC1P2 has also been shown to be involved in the regulation of neurodegenerative diseases. Several studies have shown that PABPC1P2 is involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of neuronal excitability. Therefore, PABPC1P2 has potential as a drug target for neurodegenerative diseases.

PABPC1P2 is a potential drug target for psychiatric disorders

PABPC1P2 has also been suggested to be involved in the regulation of psychiatric disorders. Several studies have shown that PABPC1P2 is involved in the regulation of anxiety, depression, and schizophrenia. Therefore, PABPC1P2 has potential as a drug target for psychiatric disorders.

Conclusion

PABPC1P2 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its functions include as a negative regulator of gene expression, and it is primarily localized to the cytoplasm of human cells. Further studies are needed to fully understand the functions of PABPC1P2 and its potential as a drug

Protein Name: Poly(A) Binding Protein Cytoplasmic 1 Pseudogene 2

The "PABPC1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PABPC1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets